One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Why Is Earlier Detection, the Key to Reducing Pancreatic Cancer, So Challenging Despite Technological Advances?.
doi : 10.1200/JCO-25-00796
Volume 43(26) pgs. 2843-2954 September 10, 2025
Inconsistent and Inaccurate Cancer Clinical Trial Reporting of Venous and Arterial Thrombotic Events: An Urgent Call to Action.
doi : 10.1200/JCO-25-00489
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
doi : 10.1200/JCO-25-00494
Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer.
doi : 10.1200/JCO.24.00287
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.
doi : 10.1200/JCO-25-00883
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma.
doi : 10.1200/JCO-24-01606
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.
doi : 10.1200/JCO-25-00225
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors.
doi : 10.1200/JCO-25-00236
Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status.
doi : 10.1200/JCO-25-00148
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.
doi : 10.1200/JCO-25-00812
Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT.
doi : 10.1200/JCO-25-00928
Reply to: Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT.
doi : 10.1200/JCO-25-01390
